Radiomics and PD-L1 expression predict immunotherapy benefits in patients with head and neck squamous cell carcinoma

Cited 0 times in

Authors: Yongsik Sim ; Beomseok Sohn ; Sooyon Kim ; Hye Ryun Kim ; Min Hee Hong ; Jinna Kim ; Seung-Koo Lee ; Sun Min Lim

MeSH: Adult ; Aged ; Antineoplastic Agents, Immunological / therapeutic use ; B7-H1 Antigen* / antagonists & inhibitors ; B7-H1 Antigen* / metabolism ; Biomarkers, Tumor ; Female ; Head and Neck Neoplasms* / diagnostic imaging ; Head and Neck Neoplasms* / drug therapy ; Head and Neck Neoplasms* / immunology ; Head and Neck Neoplasms* / mortality ; Head and Neck Neoplasms* / pathology ; Head and Neck Neoplasms* / therapy ; Humans ; Immune Checkpoint Inhibitors / therapeutic use ; Immunotherapy / methods ; Magnetic Resonance Imaging* / methods ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Nivolumab* / therapeutic use ; Prognosis ; Progression-Free Survival ; ROC Curve ; Radiomics ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck* / diagnostic imaging ; Squamous Cell Carcinoma of Head and Neck* / drug therapy ; Squamous Cell Carcinoma of Head and Neck* / immunology ; Squamous Cell Carcinoma of Head and Neck* / mortality ; Squamous Cell Carcinoma of Head and Neck* / pathology ; Squamous Cell Carcinoma of Head and Neck* / therapy

Keywords: immunotherapy ; magnetic resonance imaging ; nivolumab ; radiomics ; squamous cell carcinoma of head and neck ; survival analysis

Abstract: Aim: To evaluate the performance of MRI-derived radiomic risk score (RRS) and PD-L1 expression to predict overall survival (OS) and progression-free survival (PFS) of patients with recurrent head and neck squamous cell carcinoma receiving nivolumab therapy.Materials & methods: Three hundred forty radiomic features from pretreatment MRI were used to construct the RRS. The integrated area under the receiver operating characteristic curve (iAUC) was calculated to evaluate the performance of the RRS and PD-L1.Results: The RRS showed iAUCs of 0.69 and 0.57 for OS and PFS, respectively. PD-L1 expression showed iAUCs of 0.61 and 0.62 for OS and PFS, respectively.Conclusion: RRS and PD-L1 potentially predict the OS and PFS of patients with recurrent head and neck squamous cell carcinoma receiving nivolumab therapy.

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

Yonsei Authors: Kim, Jinna(김진아) https://orcid.org/0000-0002-9978-4356
Kim, Hye Ryun(김혜련) https://orcid.org/0000-0002-1842-9070
Sim, Yongsik(심용식) https://orcid.org/0000-0003-2711-2793
Lee, Seung Koo(이승구) https://orcid.org/0000-0001-5646-4072
Lim, Sun Min(임선민)
Hong, Min Hee(홍민희) https://orcid.org/0000-0003-3490-2195

Show full item record

YUHSpace: Radiomics and PD-L1 expression predict immunotherapy benefits in patients with head and neck squamous cell carcinoma